ISCHEMIX

Ischemix is a privately-held pharmaceutical company that is developing novel cytoprotective compounds for serious diseases and conditions... Ischemix is working to advance Cytoprotective Therapies... Ischemix, Inc. is developing novel, proprietary cytoprotective compounds for the treatment of serious diseases and conditions. Our lead compound, CMX-2043, is in preclinical development for the treatment of traumatic brain injury (TBI). CMX-2043 has produced strong preclinical data of any compound in development for TBI, as demonstrated by significant findings in controlled preclinical studies of sensorimotor activity, cognition, memory, contusion volume and hyperactive behaviour, as well as by biochemical assays. We are investigating the use of CMX-2043 for other therapeutic indications.

Also known as: Ischemix, Inc.

Primary location: Grafton United States